Publications by authors named "S Di Napoli"
Background: Monacolin-K, the active component of red yeast rice (RYR), reduces cholesterol by inhibiting HMG-CoA reductase. Following safety concerns, the European Food Safety Authority (EFSA) recommended limiting Monacolin-K intake to less than 3 mg/day due to adverse effects at higher doses.
Case Presentation: A study comparing Armolipid Plus and LopiGLIK found LopiGLIK more effective in lowering LDL cholesterol, possibly due to slightly higher dosages of Berberine and Monacolin-K.
Article Synopsis
- - This study examined how pH levels affect the piezoelectric response of dentin in root canal treated teeth by using extracted mandibular canines as specimens.
- - Thirty teeth samples were cut into small pieces and soaked in different pH solutions (4.4, 7.4, 10.4) before being tested under mechanical force.
- - Findings showed no significant differences in electrical response when force was applied vertically, but distinct variations were observed when applied along the dentinal tubules, indicating pH does influence dentin's piezoelectric properties.
The need to increase yield and enhance the sustainability of crop production systems has led to the development and employment of natural products, such as plant biostimulants. In recent years, a number of reports have researched the effects of biostimulants on plant performance; however, few studies have focused on the mutual application of microbial and/or non-microbial biostimulants. This research, conducted in the framework of the SO.
View Article and Find Full Text PDFArticle Synopsis
- CD37-targeted therapies, like naratuximab emtansine, have shown promise in treating lymphoma, demonstrating strong anti-tumor activity both alone and when combined with rituximab.
- The study investigated 54 lymphoma models, revealing that the drug's effectiveness varied with CD37 expression and discovered mechanisms of resistance related to genetic changes in cancer cells.
- Notable combinations with other drugs (anti-IL6, PI3Kδ inhibitors, and BCL2 inhibitors) improved the drug's efficacy in resistant lymphoma models, suggesting new treatment strategies for tougher cases.
The emergence of the United States Food and Drug Administration (FDA)-approved amyloid-targeting therapies for Alzheimer's disease challenges clinicians and healthcare providers with a transformative landscape. Effectively communicating the risks, benefits, burdens, costs, and available support associated with these novel disease-modifying treatments to patients, families, and other healthcare providers is essential but complex. In response, the Alzheimer's Association's Clinical Meaningfulness Workgroup has proposed language surrounding treatment eligibility, benefits, amyloid-related imaging abnormalities (ARIA), apolipoprotein E (APOE) genotyping, and treatment costs, serving as a resource to healthcare professionals in navigating discussions with patients and their families.
View Article and Find Full Text PDF